Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by RepliCel Life Sciences, Inc.
RepliCel’s Manufacturing Inspected by Japan’s PMDA
July 28, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing
July 26, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
Independent Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing
July 26, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Announces Material Patent Milestones
January 10, 2022
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
REPCF
TSX-V:RP
RepliCel Closed Final Tranche of Strategic Investment Commitment
December 21, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Terminates License Agreement with Shiseido
December 21, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
November 11, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
November 09, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
October 28, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Announces Dermal Injector Update
October 27, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
October 18, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Life Sciences Appoints One of Japan's Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
October 12, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Economy
Exposures
Economy
Tickers
REPCF
TSX-V:RP
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
September 16, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Tickers
REPCF
TSX-V:RP
RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies
July 07, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Adds Independent Director
June 15, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Tickers
REPCF
TSX-V:RP
RepliCel Launches Testing of Dermal Injector Units
May 25, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
May 19, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
May 17, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
May 11, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
REPCF
TSX-V:RP
RepliCel Announces Record Year in Patents Granted
May 05, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
REPCF
TSX-V:RP
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
May 03, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
RepliCel Closes Second Tranche of Strategic Investment Commitment
April 29, 2021
From
RepliCel Life Sciences, Inc.
Via
AccessWire
Tickers
REPCF
TSX-V:RP
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.